Katie Ewer | Academic Influence

Katie Ewer's AcademicInfluence.com Rankings

Katie Ewer

Biology

#6919

World Rank

#9736

Historical Rank

Immunology

#893

World Rank

#916

Historical Rank

Neuroscience

#2738

World Rank

#2809

Historical Rank

biology Degrees

Download Badge

Biology

Katie Ewer's Degrees

PhD Immunology University of Oxford

Why Is Katie Ewer Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Katie Jane Ewer is a British immunologist and Professor of Vaccine Immunology at the University of Oxford's Jenner Institute. Early life and education When she did not get into medical school, Ewer pursued a career in biomedical science and became interested in infectious diseases. She was interested in a career in biology for she was "fascinated by seemingly endless processes that occur in our cells and organs every second of our lives without us knowing about it. Ewer earned an undergraduate degree in biomedical science, which included a year of microbiology training. She then began working as a biomedical scientist at the microbiology department of the John Radcliffe Hospital in 2000, before pursuing a PhD on the immunology of tuberculosis . Ewer earned her PhD at the Open University as a result of her research with Ajit Lalvani on novel diagnostic tools using T cells for the diagnosis of tuberculosis infection.

(See a Problem?)

Katie Ewer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (2020) (3297)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (2020) (1480)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (2020) (1079)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials (2021) (812)
Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak (2003) (664)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial (2021) (404)
Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1 (2011) (385)
Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. (2001) (385)
Diagnosis of tuberculosis in South African children with a T cell-based assay: a prospective cohort study (2004) (385)
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (2020) (367)
Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells (2002) (345)
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. (2015) (295)
Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study (2005) (293)
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation (2013) (281)
Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species (2012) (271)
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. (2016) (232)
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (2020) (228)
Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. (2006) (226)
Prime-boost vectored malaria vaccines: Progress and prospects (2010) (217)
Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector (2012) (207)
Viral vectors as vaccine platforms: deployment in sight. (2011) (202)
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. (2012) (193)
Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. (2005) (175)
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. (2011) (161)
Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors (2012) (160)
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) (2021) (150)
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. (2004) (149)
Viral vectors as vaccine platforms: from immunogenicity to impact. (2016) (141)
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial (2020) (138)
Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. (2005) (132)
Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults (2015) (122)
Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals (2014) (121)
Screening of Highly Expressed Mycobacterial Genes Identifies Rv3615c as a Useful Differential Diagnostic Antigen for the Mycobacterium tuberculosis Complex (2008) (117)
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial (2021) (110)
Evaluation of T-Cell Responses to Novel RD1- and RD2-Encoded Mycobacterium tuberculosis Gene Products for Specific Detection of Human Tuberculosis Infection (2004) (93)
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial (2021) (93)
Characterization of a Mycobacterium tuberculosis Peptide That Is Recognized by Human CD4+ and CD8+ T Cells in the Context of Multiple HLA Alleles1 (2004) (87)
Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909 (2011) (84)
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP (2016) (81)
Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults (2013) (80)
The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world (2020) (73)
Early Diagnosis of Subclinical Multidrug-Resistant Tuberculosis (2004) (72)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (2021) (72)
Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure (2014) (64)
Chimpanzee adenoviral vectors as vaccines for outbreak pathogens (2017) (59)
Repeated tuberculin testing does not induce false positive ELISPOT results (2006) (56)
Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates (2015) (53)
A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS (2014) (53)
T-Cell–Based Diagnosis of Neonatal Multidrug-Resistant Latent Tuberculosis Infection (2007) (52)
Progress with viral vectored malaria vaccines: A multi-stage approach involving “unnatural immunity” (2015) (52)
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants (2016) (52)
Prime and target immunization protects against liver-stage malaria in mice (2017) (50)
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal (2018) (50)
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. (2014) (50)
First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children (2018) (46)
Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal (2016) (43)
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP (2018) (37)
Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection (2014) (37)
Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants (2017) (37)
Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy (2017) (35)
Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials (2018) (34)
Potency assays for novel T-cell-inducing vaccines against malaria. (2009) (33)
A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? (2017) (33)
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP (2018) (31)
(2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111. (2020) (29)
Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice (2007) (27)
Antigen Mining with Iterative Genome Screens Identifies Novel Diagnostics for the Mycobacterium tuberculosis Complex (2006) (27)
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) (2021) (26)
CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria (2018) (26)
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial (2022) (24)
Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens (2018) (24)
Is Interleukin-4δ3 Splice Variant Expression in Bovine Tuberculosis a Marker of Protective Immunity? (2007) (24)
Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection (2013) (24)
Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. (2017) (24)
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line (2019) (24)
Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man (2018) (23)
Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial (2017) (23)
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial (2021) (22)
Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells (2020) (21)
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. (2022) (21)
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine (2019) (20)
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV (2022) (19)
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells (2006) (19)
Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine (2016) (19)
Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8+ T Cells (2015) (16)
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial (2021) (15)
High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™, with Seasonal Administration to Children in Burkina Faso (2021) (14)
Characterization of two in vivo-expressed methyltransferases of the Mycobacterium tuberculosis complex: antigenicity and genetic regulation. (2008) (13)
Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors (2014) (12)
Dynamic antigen-specific point-source exposure to T-cell responses after Mycobacterium tuberculosis (2006) (11)
Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers (2019) (11)
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (2021) (10)
Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection (2021) (10)
Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid (2016) (10)
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP (2016) (9)
An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens (2017) (9)
Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus (2018) (8)
Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013–16 West Africa epidemic (2021) (8)
Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults (2014) (8)
Development of an in vitro Plasmodium parasite killing assay for the evaluation of cell-mediated immune responses following vaccination with pre-erythrocytic malaria vaccine candidates (2014) (8)
Safety and Immunogenicity of ChAd 63 and MVA ME-TRAP in West African Children and Infants (6)
Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice (2015) (6)
A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults (2021) (6)
Gene expression profiling and antigen mining of the tuberculin production strain Mycobacterium bovis AN5. (2009) (5)
Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses (2021) (4)
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination (2022) (4)
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS) (2021) (4)
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria (2022) (3)
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies (2021) (3)
DURABILITY OF IMMUNE RESPONSES INDUCED BY THREE LEADING CANDIDATE EBOLA VACCINE REGIMES; RVSV ZEBOV, CHAD3 EBO Z-MVA BN-FILO AND ADHU26. ZEBOV-MVA BN FILO (2018) (2)
THE ROLE OF REGULATORY T CELLS IN THE CONTROL OF PARASITE GROWTH AND CLINICAL OUTCOMES FOLLOWING CONTROLLED HUMAN MALARIA INFECTION IN SEMI-IMMUNE KENYAN ADULTS (2018) (2)
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (2021) (2)
Eﬃcacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial (2021) (2)
HIGH LEVEL EFFICACY IN HUMANS OF A NEXT-GENERATION PLASMODIUM FALCIPARUM ANTI-SPOROZOITE VACCINE: R21 IN MATRIX-M (TM) ADJUVANT (2017) (2)
Safety and immunogenicity of the Malaria Vaccine Candidate R21 adjuvanted with Matrix-M1 in West African adult volunteers, Burkina Faso (2017) (1)
Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso (2022) (1)
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. (2023) (1)
Diagnosis of tuberculosis (2003) (1)
From the authors [6] (2007) (1)
Heterologous Prime-Boost Schedules of Replication-Defective Adenovirus Serotype 26 and Modified Vaccinia Virus Ankara Vector Vaccines Expressing Ebola Virus Glycoprotein Are Immunogenic and Well Tolerated in Healthy Adults (2015) (1)
Development of an in vitro Plasmodium parasite killing assay for the evaluation of cell-mediated immune responses following vaccination with pre-erythrocytic malaria vaccine candidates (2014) (1)
An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens (2017) (1)
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial. (2022) (1)
Safety and Immunogenicity of a candidate MERS-CoV Viral Vectored Vaccine: a phase I, open- labelled, first-in-human, dose-escalation trial (2020) (0)
Diagnosis of tuberculosis. Authors' reply (2003) (0)
REGULATORY T CELL-MEDIATED SUPPRESSION OF HUMAN IMMUNE RESPONSES TO INVESTIGATIONAL MALARIA VACCINES (2017) (0)
Vaccination and immunotherapy against bacteria, fungi and parasites (PP-048) (2010) (0)
CLINICAL DEVELOPMENT OF VIRAL VECTORED VACCINES AGAINST MERS-COV (2018) (0)
CRYOPRESERVATION RELATED LOSS OF ANTIGEN SPECIFIC IFN gamma PRODUCING CD4+T-CELLS: LESSONS FROM A MALARIA VACCINE TRIAL SUBSTUDY (2017) (0)
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials (2023) (0)
IDENTIFICATION OF HUMAN T CELL EPITOPES IN THE EBOLAVIRUS GLYCOPROTEIN FOLLOWING VACCINATION WITH CHAD3 EBO Z GP AND MVA BN (2017) (0)
Co-infection with Schistosoma haematobium modulates the gene expression profile of malaria infection in schoolchildren in Gabon (2014) (0)
OC 8552 EFFICACY OF THE CHAD63-MVC ME-TRAP VECTORED MALARIA VACCINE CANDIDATE IN 5–17 MONTHS OLD INFANTS AND CHILDREN IN BURKINA FASO (2019) (0)
IMMUNOGENICITY OF MALARIA-VECTORED VACCINES IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMISED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES (2017) (0)
Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults (2015) (0)
Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children (2014) (0)
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response (2022) (0)
of a Novel Heterosubtypic Influenza A Vaccine, MVA2NP1M1 (2011) (0)
Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children (2014) (0)
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP (2018) (0)
Co-infection with Schistosoma haematobium modulates the gene expression profile of malaria infection in schoolchildren in Gabon (2014) (0)
A method for the diagnosis of tuberculosis (2003) (0)
SAFETY, IMMUNOGENICITY AND DURABILITY OF A NOVEL MALARIA VACCINE CANDIDATE, R21 ADJUVANTED WITH AS01(B) (2017) (0)
An in vitro T cell killing assay to assess new Plasmodium falciparum vaccine candidates (2013) (0)
Liver-stage vaccines for malaria (2013) (0)
Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults (2014) (0)
Clinical Evaluation Of New Viral Vectored Vaccines Targeting The Plasmodium Falciparum Blood-Stage Antigens; Msp1 And Ama1 (2011) (0)
A of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? (2017) (0)
SAFETY AND IMMUNOGENICITY OF A REPLICATION DEFICIENT SIMIAN ADENOVIRAL VECTORED CHIKUNGUNYA VACCINE: A PHASE I, FIRST-IN-HUMAN, DOSE ESCALATION TRIAL (2019) (0)
Chapter 8 Vaccines against SARS-CoV-2 (2022) (0)
Correction for Nébié et al., Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors (2014) (0)
Assessment of novel pre-erythrocytic malaria vaccines in humans (2017) (0)
NEUTRALIZING ANTIBODY TITERS TO SIMIAN ADENOVIRAL VECTORS FOLLOWING ADCH63 ME-TRAP IMMUNIZATION IN HUMANS (2009) (0)
Identification of M-Tuberculosis peptides that are recognized by human CD4+ and CD8+ T-cells from persons expressing different HLA alleles (2003) (0)
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP (2018) (0)
Viral vectored blood-stage malaria vaccines induce B cell responses in humans that can be boosted by controlled malaria infection (2014) (0)
A tool for evaluating heterogeneity in avidity of polyclonal antibodies (2023) (0)
MERS-CoV Spike Glycoprotein (GP) – ELISA Jenner Clinical SOP Template v1 (2020) (0)
Abstracts of the Eighth EDCTP Forum, 6–9 November 2016 (2017) (0)
Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children (2014) (0)
Stefano Colloca Induce Potent Cellular Immunity Across Multiple Species Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses (2011) (0)
Context of Multiple HLA Alleles T Cells in the + and CD8 + Human CD4 Peptide That Is Recognized by tuberculosis Mycobacterium Characterization of a (2004) (0)
Alleles T Cells in the Context of Multiple HLA + CD 8 and + Peptide That Is Recognized by Human CD 4 Mycobacterium tuberculosis Characterization of a (2004) (0)
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination (2023) (0)
Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria. (2023) (0)

This paper list is powered by the following services:

Other Resources About Katie Ewer

en.wikipedia.org

What Schools Are Affiliated With Katie Ewer?

Katie Ewer is affiliated with the following schools:

University of Oxford